SPA
AMLX icon

Sherbrooke Park Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

Sherbrooke Park Advisers’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-299,452
Closed -$850K – 888
2024
Q1 		$850K Buy
+299,452
New +$3.92M 0.17% 187

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sherbrooke Park Advisers's AMLX Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 299,452 shares — an estimated $850K sold.

Sherbrooke Park Advisers first reported a position in AMLX in Q1 2024 and held it in 1 quarter. The position peaked at $850K in Q1 2024. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 299,452 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $850K.
  • Sherbrooke Park Advisers first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Amylyx Pharmaceuticals position peaked at $850K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.